Bionano Genomics Q4 revenue down 24% YoY to $8.2M; full-year revenue $30.8M, down 15%

Bionano Genomics, Inc.

2025-Q1 EPS reported -$1.15 revenue$6,457,000

Q4 2024 revenue $8.2M vs $10.8M in Q4 2023, decline driven by discontinued clinical services; core product revenue 1% higher for full year.
GAAP gross margin improved to 42% from 23% YoY; GAAP operating expense cut to $15.4M from $27.4M.
Full-year product revenue $27.0M (+1% YoY) with consumables +14% and software +11%; instruments down ~$2M.
Installed OGM systems 371 (+14% YoY); flowcell sales 30,307 (+15% YoY); 336 OGM publications in 2024.
Cash & securities $20.9M at year-end (incl. $11.4M restricted); raised $10M in Jan 2025 offering; modified debentures to reduce payments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.